Cancer Research and Treatment

Volume 37(3); June 2005

Original Articles

High-Dose Chemotherapy of Cyclophosphamide, Thiotepa and Carboplatin (CTCb) followed by Autologous Stem-Cell Transplantation as a Consolidation for Breast Cancer Patients with 10 or more Positive Lymph Nodes: a 5-Year follow-Up Results: Hee-Jung Sohn, Sang-Hee Kim, Gyeong-Won Lee, Shin Kim, Jin-Hee Ahn, Sung-Bae Kim, Sang-We Kim, Woo Kun Kim, Cheolwon Suh; Cancer Res Treat. 2005;37(3):137-142. Published online June 30, 2005; DOI: https://doi.org/10.4143/crt.2005.37.3.137

Purpose

The benefit of consolidation high-dose chemotherapy (HDC) for high-risk primary breast cancer is controversial. We evaluated the efficacy and safety of consolidation HDC with cyclophosphamide, thiotepa and carboplatin (CTCb) followed by autologous stem-cell transplantation (ASCT) in resected breast cancer patients with 10 or more positive lymph nodes.

Materials and Methods

Between December 1994 and April 2000, 22 patients were enrolled. All patients received 2 to 6 cycles of adjuvant chemotherapy after surgery for breast cancer. The HDC regimen consisted of cyclophosphamide 1,500 mg/m²/day, thiotepa 125 mg/m²/day and carboplatin 200 mg/m²/day intravenous for 4 consecutive days.

Results

With a median follow-up of 58 months, 11 patients recurred and died. The median disease-free survival (DFS) and median overall survival (OS) were 49 and 69 months, respectively. The 5-year DFS and OS rates were 50% and 58%, respectively. The 12 patients with 10 to 18 involved nodes had better 5-year DFS (67%) and OS (75%) than 10 patients with more than 18 involved nodes (30% and 38%, respectively). The most common grade 3 or 4 nonhematologic toxicity was diarrhea, which occurred in 5 patients (23%). No treatment-related death was observed.

Conclusion

Consolidation HDC with CTCb followed by ASCT for resected breast cancer with more than 10 positive nodes had an acceptable toxicity but does not show promising survival.

Citations

Citations to this article as recorded by

Real-world Experience of Improvement in the Survival of Lymphoma and Myeloma Patients with Autologous Stem Cell Transplantation over a 25-year Period
Hyungwoo Cho, Shin Kim, Kyoungmin Lee, Jung Sun Park, Cheolwon Suh
The Korean Journal of Medicine.2021; 96(6): 501. CrossRef
Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45)
X. Wang, J. Ren, J. Zhang, Y. Yan, N. Jiang, J. Yu, L. Di, G. Song, L. Che, J. Jia, X. Zhou, H. Yang, H. K. Lyerly
Clinical and Translational Oncology.2016; 18(1): 82. CrossRef

9,336 View
45 Download
2 Crossref

The Surgeon's Expertise-Outcome Relationship in Gastric Cancer Surgery: Wansik Yu, Young Kook Yun, Ilwoo Whang, Gyu Seok Choi; Cancer Res Treat. 2005;37(3):143-147. Published online June 30, 2005; DOI: https://doi.org/10.4143/crt.2005.37.3.143

Abstract PDF PubReader ePub

Purpose

The surgical caseload or duration of practice of a surgeon may influence the outcomes of gastric cancer surgery. This study aimed to clarify the surgical quality provided by specialized gastric cancer surgeons.

Materials and Methods

The postoperative courses of 1,877 patients who underwent surgery for gastric cancer were retrospectively reviewed. For classification of the surgeon's expertise, the number of yearly resections performed by, and consecutive years of practice of, the surgeons were used. The outcome measures used were the 30-day mortality and long-term survival.

Results

Surgical mortalities of patients who underwent surgery by a specialized surgeon and those by a general surgeon revealed no statistically significant difference. A significant difference in the five-year survival rates was found with surgeons with at least two consecutive years of practice compared to those with less than two years, when 50 or more cases had been conducted per year (63.9% and 59.7%; p=0.0380). In cases of four-years of consecutive practice, the five-year survival rate was significantly improved, even if only 10 cases were performed annually (64.9% and 58.3%; p=0.0023), although the best survival rate was found with surgeons that had performed 50 or more surgeries per year.

Conclusion

Improved survival rates, with acceptable surgical mortality, can be achieved for gastric cancer when the surgery is performed by a specialized surgeon. A specialized gastric cancer surgeon can be defined as one who has operated on more than 50 new cases per year, with 2 or more consecutive years of surgical practice.

Citations

Citations to this article as recorded by

Lymphadenectomy for Gastric Cancer
Jenny Hwang, Jacquelyn Carr
Surgical Clinics of North America.2025; 105(1): 47. CrossRef
Associations of Annual Hospital and Surgeon Volume with Patient Outcomes After Gastrectomy: A Systematic Review and Meta-analysis
Jiafu Ji, Leiyu Shi, Xiangji Ying, Xinpu Lu, Fei Shan
Annals of Surgical Oncology.2022; 29(13): 8276. CrossRef
Keratinocyte cancer with incidental perineural invasion: A registry analysis of management and 5‐year outcomes
Agnieszka Adams, Brian De’Ambrosis, Ben Panizza, Paul Belt, James Emmett, Tim Warren, David C. Whiteman
Australasian Journal of Dermatology.2020; 61(3): 226. CrossRef
Operation time as a simple indicator to predict the overcoming of the learning curve in gastric cancer surgery: a multicenter cohort study
Tae-Han Kim, Keun Won Ryu, Jun Ho Lee, Gyu-Seok Cho, Woo Jin Hyung, Chan-Young Kim, Min-Chan Kim, Seung Wan Ryu, Dong Woo Shin, Hyuk-Joon Lee
Gastric Cancer.2019; 22(5): 1069. CrossRef
Are treatment outcomes in gastric cancer associated with either hospital volume or surgeon volume?
Yosuke Mukai, Yukinori Kurokawa, Shuji Takiguchi, Masaki Mori, Yuichiro Doki
Annals of Gastroenterological Surgery.2017; 1(3): 186. CrossRef
Full robot-assisted gastrectomy: surgical technique and preliminary experience from a single center
Yolanda Quijano, Emilio Vicente, Benedetto Ielpo, Hipolito Duran, Eduardo Diaz, Isabel Fabra, Luis Malave, Valentina Ferri, Antonio Ferronetti, Carlos Plaza, Vito D’Andrea, Riccardo Caruso
Journal of Robotic Surgery.2016; 10(4): 297. CrossRef
The positive impact of surgeon specialization on survival for gastric cancer patients after surgery with curative intent
Yuexiang Liang, Liangliang Wu, Xiaona Wang, Xuewei Ding, Han Liang
Gastric Cancer.2015; 18(4): 859. CrossRef
Moderating Effect of Structural Complexity on the Relationship between Surgery Volume and in Hospital Mortality of Cancer Patients
Kyungil Youn
Health Policy and Management.2014; 24(4): 380. CrossRef
Robot-Assisted Gastrectomy With Lymph Node Dissection for Gastric Cancer
Jyewon Song, Sung Jin Oh, Wook Ho Kang, Woo Jin Hyung, Seung Ho Choi, Sung Hoon Noh
Annals of Surgery.2009; 249(6): 927. CrossRef

8,508 View
46 Download
9 Crossref

Multidimensional Constructs of the EORTC Quality of Life Questionnaire (QLQ-C30) in Korean Cancer Patients with Heterogeneous Diagnoses: Eun-Hyun Lee, Mison Chun, Hee-Jung Wang, Ho Yeong Lim, Jin-Hyuk Choi; Cancer Res Treat. 2005;37(3):148-156. Published online June 30, 2005; DOI: https://doi.org/10.4143/crt.2005.37.3.148

Abstract PDF PubReader ePub

Purpose

The aim of this study was to evaluate the multidimensional constructs of the EORTC Quality of Life Questionnaire (QLQ-C30) in patients with cancer, employing not only the commonly used multitrait scaling analysis and interscale correlations, but also the factorial and multidimensional scaling (MDS) analyses.

Materials and Methods

A total of 334 Korean cancer patients participated in this cross-sectional study. All patients completed the QLQ-C30.

Results

With the multitrait scaling analysis, the cognitive functioning scale did not meet item convergent and divergent validities. With the interscale correlations, the physical and role functioning scales were found to be highly correlated; this was also evident in the factorial analysis. The MDS showed that each item within the social, emotional, global health status/quality of life, and nausea/vomiting scales were clustered close together, but far from those of the other scales.

Conclusion

The authors conclude that the four way evaluation of the QLQ-C30 produced results that supported the original hypothesized constructs. However, the physical and role functioning scales were not distinctive, and that of the cognitive functioning was somewhat problematic in the Korean population with cancer.

Citations

Citations to this article as recorded by

Validation of Gujarati Version of European Organization for Research and Treatment of Cancer Quality of Life Modules in Head and Neck Cancer Patients of Western India
Sujal Parkar, Abhishek Sharma, Mihir Shah
Indian Journal of Otolaryngology and Head & Neck Surgery.2022; 74(S2): 2291. CrossRef
Psychometric property of an instrument 1: content validity
Eun-Hyun Lee
Korean Journal of Women Health Nursing.2021; 27(1): 10. CrossRef
Development of an Instrument to Assess the Nursing Professional Pride
JaeHee Jeon, EunHee Lee, EunJoo Kim
Journal of Korean Academy of Nursing.2020; 50(2): 228. CrossRef
Reliability and Validity of the Arabic Version of the EORTC QLQ-C30 and QLQ-BR23 Questionnaires

Ghufran Jassim, Ahmed AlAnsari
Neuropsychiatric Disease and Treatment.2020; Volume 16: 3045. CrossRef
Predictive Factors of Overall Well-Being Using the EORTC QLQ-C15-PAL Extracted from the EORTC QLQ-C30
Kinsey Lam, Liang Zeng, Liying Zhang, Ling-Ming Tseng, Ming-Feng Hou, Alysa Fairchild, Vassilios Vassiliou, Reynaldo Jesus-Garcia, Mohamed A. Alm El-Din, Aswin Kumar, Fabien Forges PharmD, Wei-Chu Chie, Arjun Sahgal, Michael Poon, Edward Chow
Journal of Palliative Medicine.2013; 16(4): 402. CrossRef
Development and Validation of the Hospice Palliative Care Performance Scale
So-Hi Kwon
Journal of Korean Academy of Nursing.2011; 41(3): 374. CrossRef
Translation and Validation of EORTC QLQ-C30 into Indonesian Version for Cancer Patients in Indonesia
D. A. Perwitasari, J. Atthobari, I. Dwiprahasto, M. Hakimi, H. Gelderblom, H. Putter, J. W. R. Nortier, H.-J. Guchelaar, A. A. Kaptein
Japanese Journal of Clinical Oncology.2011; 41(4): 519. CrossRef
Psychometric Evaluation of a Need Scale for Cancer Patients Undergoing Follow-up Care
Eun-Hyun Lee, Seongmi Moon, Soo-Yeon Cho, Young Taek Oh, Mison Chun, Sung Hwan Kim, Jae-Sung Kim, Hye Kyung Kim
Journal of Korean Academy of Nursing.2010; 40(4): 551. CrossRef

18,022 View
103 Download
8 Crossref

Assessment of Tumor Regression by Consecutive Pelvic Magnetic Resonance Imaging and Dose Modification during High-Dose-Rate Brachytherapy for Carcinoma of the Uterine Cervix: Taek-Keun Nam, Byung-Sik Nah, Ho-Sun Choi, Woong-Ki Chung, Sung-Ja Ahn, Seok-Mo Kim, Ju-Young Song, Mi-Seon Yoon; Cancer Res Treat. 2005;37(3):157-164. Published online June 30, 2005; DOI: https://doi.org/10.4143/crt.2005.37.3.157

Abstract PDF PubReader ePub

Purpose

To assess tumor regression, as determined by pelvic magnetic resonance imaging (MRI), and evaluate the efficacies and toxicities of the interim brachytherapy (BT) modification method, according to tumor regression during multi-fractionated high-dose-rate (HDR) BT for uterine cervical cancer.

Materials and Methods

Consecutive MRI studies were performed pre-radiotherapy (RT), pre-BT and during interfraction of BT (inter-BT) in 69 patients with cervical cancer. External beam radiotherapy (EBRT) was performed, using a 10 MV X-ray, in daily fraction of 1.8 Gy with 4-fields, 5 d/wk. Radiation was delivered up to 50.4 Gy, with midline shielding at around 30.6 Gy. Of all 69 patients, 50 received modified interim BT after checking the inter-BT MRI. The BT was delivered in two sessions; the first was composed of several 5 Gy fractions to point A, twice weekly, using three channel applicators. According to the three measured orthogonal diameters of the regressed tumor, based on inter-BT MR images, the initial BT plan was modified, with the second session consisting of a few fractions of less than 5 Gy to point A, using a cervical cylinder applicator.

Results

The numbers of patients in FIGO stages Ib, IIa, IIb and IIIb+IVa were 19 (27.5%), 18 (26.1%), 27 (39.2%) and 5 (7.2%), respectively. Our treatment characteristics were comparable to those from the literatures with respect to the biologically effective dose (BED) to point A, rectum and bladder as reference points. In the regression analysis a significant correlation was observed between tumor regression and the cumulative dose to point A on the follow-up MRI. Nearly 80% regression of the initial tumor volume occurred after 30.6 Gy of EBRT, and this increased to 90% after an additional 25 Gy in 5 fractions of BT, which corresponds to 73.6 Gy of cumulative BED₁₀ to point A. The median total fraction number, and those at the first and second sessions of BT were 8 (5~10), 5 (3~7) and 3 (1~5), respectively. The median follow-up time was 53 months (range, 9~66 months). The 4-year disease-free survival rate of all patients was 86.8%. Six (8.7%) patients developed pelvic failures, but major late complications developed in only two (2.9%).

Conclusion

Our study shows that effective tumor control, equivalent survival and low rates of major complications can be achieved by modifying the fraction size during BT according to tumor regression, as determined by consecutive MR images. We recommend checking the follow-up MRI at a cumulative BED₁₀ of around 65 Gy to point A, with the initial BT modified at a final booster BT session.

Citations

Citations to this article as recorded by

Correlations of UICC tumor stage and tumor regression on T2-weighted MRI sequences during definitive radiotherapy of cervical cancer
Florian Arend, Markus Oechsner, Clara B. Weidenbächer, Stephanie E. Combs, Kai J. Borm, Marciana N. Duma
Tumori Journal.2021; 107(2): 139. CrossRef
Target volume changes through high-dose-rate brachytherapy for cervical cancer when evaluated on high resolution (3.0 Tesla) magnetic resonance imaging
Wenqing Sun, Sudershan K. Bhatia, Geraldine M. Jacobson, Ryan T. Flynn, Yusung Kim
Practical Radiation Oncology.2012; 2(4): e101. CrossRef
Metabolic Response of Lymph Nodes Immediately After RT Is Related With Survival Outcome of Patients With Pelvic Node-Positive Cervical Cancer Using Consecutive [18F]fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography
Mee Sun Yoon, Sung-Ja Ahn, Byung-Sik Nah, Woong-Ki Chung, Ho-Chun Song, Su Woong Yoo, Ju-Young Song, Jae-Uk Jeong, Taek-Keun Nam
International Journal of Radiation Oncology*Biology*Physics.2012; 84(4): e491. CrossRef

11,180 View
65 Download
3 Crossref

Expression of Cyclooxygenase-2 in Human Breast Cancer: Relationship with HER-2/neu and other Clinicopathological Prognostic Factors: Eunmi Nam, Soon Nam Lee, Seock-Ah Im, Do-Yeun Kim, Kyoung Eun Lee, Sun Hee Sung; Cancer Res Treat. 2005;37(3):165-170. Published online June 30, 2005; DOI: https://doi.org/10.4143/crt.2005.37.3.165

Abstract PDF PubReader ePub

Purpose

Previous epidemiologic studies have demonstrated that nonsteroidal anti-inflammatory drugs can reduce the risk of breast cancer, and this possibly happens via cyclooxygenase (COX) inhibition. Moreover, growth factor-inducible COX-2, which is overexpressed in neoplastic tissue, is an attractive therapeutic target. Thus, we evaluated the expression of COX-2 in breast cancer tissues, and we assessed the association between COX-2 expression and HER-2/neu expression and also with several clinicopathological features.

Materials and Methods

We analyzed the surgical specimens from 112 women with breast cancer who had undergone lumpectomy or mastectomy. The expressions of COX-2, HER-2/neu, MMP-2 and TIMP-2 were determined immunohistochemically. The correlations between COX-2 expression and several variables, including clinicopathological factors, HER-2/neu expression, MMP-2 expression and TIMP-2 expression were analyzed. Survival analysis was also performed with respect to COX-2 overexpression.

Results

The overexpression of COX-2 protein was observed in 28.6% of the breast cancer tissues. Tumors with lymph node metastasis more frequently showed COX-2 overexpression than did those tumors without metastasis (p=0.039), and the increased COX-2 expression correlated positively with HER-2/neu overexpression (p=0.000). No significant differences were found for the MMP-2 or TIMP-2 expression rates in the COX-2 positive and negative groups. The survival analysis revealed no significant differences according to the COX-2 expression.

Conclusion

This study results suggest that increased COX-2 expression is related with the progression of breast cancer, e.g., with lymph node invasion. COX-2 overexpression found to be related with HER-2/neu overexpression, but not with MMP-2 or TIMP-2 expression. These results support the potential use of selective agents that inhibit COX-2 or HER-2/neu for the management of breast cancer.

Citations

Citations to this article as recorded by

Postoperative administration of ketorolac averts morphine-induced angiogenesis and metastasis in triple-negative breast cancer
Zhongqi Liu, Shi Cheng, Ganglan Fu, Fengtao Ji, Chengli Wang, Minghui Cao
Life Sciences.2020; 251: 117604. CrossRef
Functional analysis of polymorphisms in the COX-2 gene and risk of lung cancer
Joyce L. Moraes, Amanda B. Moraes, Veronica Aran, Marcelo R. Alves, Luciene Schluckbier, Mariana Duarte, Edson Toscano, Mauro Zamboni, Cinthya Sternberg, Emanuela de Moraes, José R. Lapa E Silva, Carlos Gil Ferreira
Molecular and Clinical Oncology.2017; 6(4): 494. CrossRef
Cyclooxygenase-2 Expression in Invasive Breast Carcinomas of No Special Type and Correlation with Pathological Profiles Suggest a Role in Tumorigenesis Rather than Cancer Progression
Nurul Akmar Misron, Lai-Meng Looi, Nik Raihan Nik Mustapha
Asian Pacific Journal of Cancer Prevention.2015; 16(4): 1553. CrossRef
Stromal, rather than epithelial cyclooxygenase-2 (COX-2) expression is associated with overall survival of breast cancer patients
Justyna Urban, Łukasz Kuźbicki, Grzegorz Szatkowski, Agata Stanek-Widera, Dariusz Lange, Barbara W Chwirot
BMC Cancer.2014;[Epub] CrossRef
Prognostic influence of cyclooxygenase-2 protein and mRNA expression in node-negative breast cancer patients
Isabel Sicking, Karlien Rommens, Marco J Battista, Daniel Böhm, Susanne Gebhard, Antje Lebrecht, Cristina Cotarelo, Gerald Hoffmann, Jan G Hengstler, Marcus Schmidt
BMC Cancer.2014;[Epub] CrossRef

10,068 View
70 Download
5 Crossref

Co-Expression of Cox-2, C-Met and β-catenin in Cells Forming Invasive front of Gallbladder Cancer: Woo Sung Moon, Ho Sung Park, Ho Lee, Rama Pai, Andrzej S. Tarnawski, Kyung Ryoul Kim, Kyu Yun Jang; Cancer Res Treat. 2005;37(3):171-176. Published online June 30, 2005; DOI: https://doi.org/10.4143/crt.2005.37.3.171

Abstract PDF PubReader ePub

Purpose

Gallbladder cancer is a malignancy with poor prognosis, predominantly resulting from invasion and metastasis. Our previous studies have demonstrated that prostaglandin E₂ (PGE₂), generated by cyclooxygenase 2 (Cox-2), transactivates epidermal growth factor receptor (EGFR), c-Met and β-catenin; thus, enhancing colon cancer cell growth and invasiveness in vitro. To determine whether these findings are applicable to clinical conditions, we examined the expression and cellular localization/co-localization of Cox-2, c-Met, β-catenin, EGFR and c-erbB2 in gallbladder cancer.

Materials and Methods

Thirty-five specimens of invasive gallbladder cancer, 8 in situ carcinoma and 7 adenoma specimens were immunostained with specific antibodies against Cox-2, c-Met, β-catenin, EGFR and c-erbB2. The cellular distribution, localization and colocalization were examined, and the signal intensities quantified in: a) the central area of gallbladder cancer and b) cancer cells forming the invasive front.

Results

Cox-2, c-Met, β-catenin, c-erbB2 and EGFR were over-expressed in 80, 74, 71, 62 and 11% of invasive gallbladder cancers, respectively. β-catenin was expressed in 80% of non-malignant specimens, exclusively in the cell membrane, while the cancer specimens showed cytoplasmic and/or nuclear staining. Significantly higher Cox-2, c-Met and β-catenin expressions were present in cancer cells of the invasive front than in the tumor central areas (p<0.001), and these expressions were significantly (p=0.01) associated with the invasion depth. Co-expressions of Cox-2, c-Met, β-catenin and c-erbB2 were present in 42% of the specimens in cancer cells forming the invasive front.

Conclusion

The overexpressions, and often co-localizations, of Cox-2, c-Met and β-catenin in cancer cells forming the invasive front indicate their local interactions and important roles in invasion.

Citations

Citations to this article as recorded by

Arachidonic acid metabolism as a novel pathogenic factor in gastrointestinal cancers
Weiqin Lu, Aihemaitijiang Aihaiti, Paziliya Abudukeranmu, Yajun Liu, Huihui Gao
Molecular and Cellular Biochemistry.2025; 480(2): 1225. CrossRef
EGFR, HER2, and MET gene amplification and protein expression profiles in biliary tract cancer and their prognostic significance
Yeseul Kim, Seungyun Jee, Hyunsung Kim, Seung Sam Paik, Dongho Choi, Su Hyun Yoo, Su-Jin Shin
The Oncologist.2024; 29(8): e1051. CrossRef
Immunohistochemical appraisal of epithelial mesenchymal transition type III in gall bladder cancer
Kamini Yadav, Preeti Agarwal, Madhu Kumar, Sameer Gupta, Medha Mishra, Malti Kumari Maurya, Sumaira Qayoom, Madhu Mati Goel
Indian Journal of Pathology and Microbiology.2023; 66(1): 44. CrossRef
Krukenberg Tumor Related to Gallbladder Cancer in a Young Woman: A Case Report and Review of the Literature
Giulia Grizzi, Michele Ghidini, Margherita Ratti, Marianna D’Ercole, Giulia Tanzi, Annalisa Abbiati, Andrea Celotti, Daniele Spada, Gian Luca Baiocchi, Maria Bonomi
Journal of Personalized Medicine.2023; 13(6): 957. CrossRef
Design, synthesis and evaluation of 4,7-disubstituted 8-methoxyquinazoline derivatives as potential cytotoxic agents targeting β-catenin/TCF4 signaling pathway
Kaushik Neogi, Prashant R. Murumkar, Priyanshu Sharma, Poonam Yadav, Mallika Tewari, Devarajan Karunagaran, Prasanta Kumar Nayak, Mange Ram Yadav
Translational Oncology.2022; 19: 101395. CrossRef
Transcription factor 4 expression and correlation with tumor progression in gallbladder cancer
Kaushik Neogi, Mallika Tewari, Ashish Kumar Singh, Kavyanjali Sharma, Gullanki Naga Venkata Charan Tej, Sumit Singh Verma, Subash Chandra Gupta, Prasanta Kumar Nayak
Journal of Cancer Research and Therapeutics.2022; 18(3): 668. CrossRef
Gallbladder Cancer: Current Multimodality Treatment Concepts and Future Directions
Niklas Sturm, Jasmin Selina Schuhbaur, Felix Hüttner, Lukas Perkhofer, Thomas Jens Ettrich
Cancers.2022; 14(22): 5580. CrossRef
Knockdown of SLC39A4 Expression Inhibits the Proliferation and Motility of Gallbladder Cancer Cells and Tumor Formation in Nude Mice
Min Li, Kun Fan, Bohao Zheng, David Zekria, Tao Suo, Han Liu, Sheng Shen, Houbao Liu, Xiaoling Ni
Cancer Management and Research.2021; Volume 13: 2235. CrossRef
Aspirin and Statin Use and the Risk of Gallbladder Cancer
Kritika Prasai, Sri Harsha Tella, Siddhartha Yadav, Anuhya Kommalapati, Kristin Mara, Mohamed Mady, Mohamed A. Hassan, Nicha Wongjarupong, Natalia Rodriguez-Payan, Mitesh Borad, Tushar Patel, Lewis R. Roberts, Amit Mahipal
Cancers.2021; 13(5): 1186. CrossRef
Molecular Targets and Emerging Therapies for Advanced Gallbladder Cancer
Matteo Canale, Manlio Monti, Ilario Giovanni Rapposelli, Paola Ulivi, Francesco Giulio Sullo, Giulia Bartolini, Elisa Tiberi, Giovanni Luca Frassineti
Cancers.2021; 13(22): 5671. CrossRef
UCP2 promotes proliferation and chemoresistance through regulating the NF-κB/β-catenin axis and mitochondrial ROS in gallbladder cancer
Jianhua Yu, Lawrence Shi, Weiguo Lin, Baochun Lu, Yunfeng Zhao
Biochemical Pharmacology.2020; 172: 113745. CrossRef
Prevalence and Clinicopathological Significance of MET Overexpression and Gene Amplification in Patients with Gallbladder Carcinoma
Yeseul Kim, Seong Sik Bang, Seungyun Jee, Sungeon Park, Su-Jin Shin, Kiseok Jang
Cancer Research and Treatment.2020; 52(2): 481. CrossRef
Genetic mutational analysis of β-catenin gene affecting GSK-3β phosphorylation plays a role in gallbladder carcinogenesis: Results from a case control study
Ruhi Dixit, Manoj Pandey, Sunil Kumar Tripathi, Amit Nandan Dhar Dwivedi, Vijay Kumar Shukla
Cancer Treatment and Research Communications.2020; 23: 100173. CrossRef
Overview of current targeted therapy in gallbladder cancer
Xiaoling Song, Yunping Hu, Yongsheng Li, Rong Shao, Fatao Liu, Yingbin Liu
Signal Transduction and Targeted Therapy.2020;[Epub] CrossRef
Targeting Lipid Peroxidation for Cancer Treatment
Sofia M. Clemente, Oscar H. Martínez-Costa, Maria Monsalve, Alejandro K. Samhan-Arias
Molecules.2020; 25(21): 5144. CrossRef
β-Catenin expression is associated with cell invasiveness in pancreatic cancer
Jin Niang Nan, Ok Ran Kim, Myung Ah Lee
The Korean Journal of Internal Medicine.2019; 34(3): 618. CrossRef
Epithelial-to-mesenchymal transition in gallbladder cancer: from clinical evidence to cellular regulatory networks
Sunwang Xu, Ming Zhan, Jian Wang
Cell Death Discovery.2017;[Epub] CrossRef
New Horizons for Precision Medicine in Biliary Tract Cancers
Juan W. Valle, Angela Lamarca, Lipika Goyal, Jorge Barriuso, Andrew X. Zhu
Cancer Discovery.2017; 7(9): 943. CrossRef
Molecular genetics and targeted therapeutics in biliary tract carcinoma
Eric I Marks
World Journal of Gastroenterology.2016; 22(4): 1335. CrossRef
CIZ1 promoted the growth and migration of gallbladder cancer cells
Dexiang Zhang, Yueqi Wang, Yuedi Dai, Jiwen Wang, Tao Suo, Hongtao Pan, Han Liu, Sheng Shen, Houbao Liu
Tumor Biology.2015; 36(4): 2583. CrossRef
Prognostic significance of COX-2 and β-catenin in colorectal carcinoma
Amani Kazem, Khaled El Sayed, Yasser El Kerm
Alexandria Journal of Medicine.2014; 50(3): 211. CrossRef
A genetic model for gallbladder carcinogenesis and its dissemination
S.G. Barreto, A. Dutt, A. Chaudhary
Annals of Oncology.2014; 25(6): 1086. CrossRef
The Role of Epidermal Growth Factor Receptor in Cancer Metastasis and Microenvironment
Takamitsu Sasaki, Kuniyasu Hiroki, Yuichi Yamashita
BioMed Research International.2013; 2013: 1. CrossRef
Significance of epithelial growth factor in the epithelial–mesenchymal transition of human gallbladder cancer cells
Takamitsu Sasaki, Hiroki Kuniyasu, Yi Luo, Daisuke Kato, Satoshi Shinya, Kiyomu Fujii, Hitoshi Ohmori, Yuichi Yamashita
Cancer Science.2012; 103(6): 1165. CrossRef
E-cadherin and c-Met expression in actinic cheilits and lip squamous cell carcinoma
A. Martínez, M.L. Spencer, J. Borlando, M. Flores, I.G. Rojas
Revista Clínica de Periodoncia, Implantología y Rehabilitación Oral.2011; 4(3): 122. CrossRef

10,666 View
63 Download
25 Crossref

Intensity of Tumor Budding as an Index for the Malignant Potential in Invasive Rectal Carcinoma: Sang-Sik Ha, Hong-Jo Choi, Ki-Jae Park, Jung-Min Kim, Sung-Heun Kim, Young-Hoon Roh, Hyuk-Chan Kwon, Mee-Sook Roh; Cancer Res Treat. 2005;37(3):177-182. Published online June 30, 2005; DOI: https://doi.org/10.4143/crt.2005.37.3.177

Abstract PDF PubReader ePub

Purpose

The aim of this study was to quantitatively assess the intensity of tumor budding in rectal carcinoma and to determine how it correlates with the malignant potential.

Materials and Methods

Intensities of the tumor budding at the invasive front of the surgical specimens from 90 patients (male, 51) with well- or moderately-differentiated rectal carcinoma were investigated. Differences in the budding intensity among pathologic variables were compared, and recurrences and survivals were analyzed in accordance with degree of the budding intensity. The patients ranged in age from 33 to 75 years (mean, 55.4) with the median follow-up being 43 months (range, 12~108).

Results

Tumor budding was identified in 89 patients (98.9%) with a mean intensity of 7.5±5.3. The budding intensity was significantly higher in tumors with lymphatic invasion (p=0.0081), blood vessel invasion (p<0.0001), and perineural invasion (p=0.0013) than in those tumor without these findings. It became significantly higher with the increase in nodal stage (p<0.0001). The intensity of tumor budding in patients with relapse (29 patients) was significantly higher than that in patients without relapse (6.2±5.0 vs. 10.2±4.9; p=0.0005), but this difference in the intensity was observed only for the node-positive patients (8.0±3.4 vs. 11.9±5.1; p=0.0064). When the patients were stratified into two groups on either side of the mean of the intensity, the higher intensity group showed a significantly less favorable disease-free (DFS) and overall survival (OS) (p=0.0026 and 0.0205, respectively). Based on the multivariate analysis, the nodal stage and the intensity of budding proved to be the independent variables associated with DFS (p=0.023 and 0.03, respectively).

Conclusion

Tumor budding at the invasive margin is a reliable pathologic index that indicates a higher malignant potential and a less favorable prognosis for patients with advanced rectal carcinoma.

Citations

Citations to this article as recorded by

Analysis of tumor budding as a prognostic factor for recurrence in patients with stage II and III colon cancer. Experience in a tertiary hospital
Antonio Rueda-Lara, David Viñal, Daniel Martínez-Pérez, María Alameda-Guijarro, Gema Martin-Montalvo, Sergio Martínez-Recio, Jesús Peña-Lopez, Diego Jiménez-Bou, Icíar Ruíz-Gutiérrez, Andrea García-Leal, Patricia Zwisler-Contreras, Ismael Ghanem, Ana Belé
The Oncologist.2025;[Epub] CrossRef
Polyploid giant cancer cells and cancer progression
Xinyue Zhou, Mingming Zhou, Minying Zheng, Shifeng Tian, Xiaohui Yang, Yidi Ning, Yuwei Li, Shiwu Zhang
Frontiers in Cell and Developmental Biology.2022;[Epub] CrossRef
Tumor Budding as a Prognostic Marker in Rectal Cancer Patients on Propensity Score Analysis
Jung Kyong Shin, Yoon Ah Park, Jung Wook Huh, Seong Hyeon Yun, Hee Cheol Kim, Woo Yong Lee, Seok Hyung Kim, Sang Yun Ha, Yong Beom Cho
Annals of Surgical Oncology.2021; 28(13): 8813. CrossRef
Immunohistochemical evaluation of tumor budding for stratifying T1 colorectal cancer: optimal cut-off value and a novel computer-assisted semiautomatic method
Manabu Takamatsu, Hiroshi Kawachi, Noriko Yamamoto, Maki Kobayashi, Yuka Toyama, Takashi Maekawa, Akiko Chino, Shoichi Saito, Masashi Ueno, Yutaka Takazawa, Yuichi Ishikawa
Modern Pathology.2019; 32(5): 675. CrossRef
Tumor Budding: Prognostic Value in Muscle-invasive Bladder Cancer
Laura Lorenzo Soriano, Guzmán Ordaz Jurado, José Luis Pontones Moreno, Sara Villarroya Castillo, Soraya Hernández Girón, Iván Sáez Moreno, David Ramos Soler
Urology.2019; 130: 93. CrossRef
RAS, Cellular Plasticity, and Tumor Budding in Colorectal Cancer
Valeria Maffeis, Lorenzo Nicolè, Rocco Cappellesso
Frontiers in Oncology.2019;[Epub] CrossRef
Prognostic Impact of Tumor-Budding Grade in Stages 1–3 Colon Cancer: A Retrospective Cohort Study
Bo Young Oh, Yoon Ah Park, Jung Wook Huh, Seong Hyeon Yun, Hee Cheol Kim, Ho-Kyung Chun, Seok Hyung Kim, Sang Yun Ha, Woo Yong Lee, Yong Beom Cho
Annals of Surgical Oncology.2018; 25(1): 204. CrossRef
Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching
Linde De Smedt, Sofie Palmans, Daan Andel, Olivier Govaere, Bram Boeckx, Dominiek Smeets, Eva Galle, Jasper Wouters, David Barras, Madeleine Suffiotti, Jeroen Dekervel, Thomas Tousseyn, Gert De Hertogh, Hans Prenen, Sabine Tejpar, Diether Lambrechts, Xavi
British Journal of Cancer.2017; 116(1): 58. CrossRef
Tumour budding in colorectal cancer: what do we know and what can we do?
Linde De Smedt, Sofie Palmans, Xavier Sagaert
Virchows Archiv.2016; 468(4): 397. CrossRef
Tumor Budding: The Name is EMT. Partial EMT.
Alexandru Grigore, Mohit Jolly, Dongya Jia, Mary Farach-Carson, Herbert Levine
Journal of Clinical Medicine.2016; 5(5): 51. CrossRef
The relationship between tumour budding, the tumour microenvironment and survival in patients with primary operable colorectal cancer
Hester C van Wyk, James H Park, Joanne Edwards, Paul G Horgan, Donald C McMillan, James J Going
British Journal of Cancer.2016; 115(2): 156. CrossRef
Tumor Budding, Micropapillary Pattern, and Polyploidy Giant Cancer Cells in Colorectal Cancer: Current Status and Future Prospects
Shiwu Zhang, Dan Zhang, Zhengduo Yang, Xipeng Zhang, Chuanwei Yang
Stem Cells International.2016;[Epub] CrossRef
The role of tumour budding in predicting survival in patients with primary operable colorectal cancer: A systematic review
H.C. van Wyk, James Park, Campbell Roxburgh, Paul Horgan, Alan Foulis, Donald C. McMillan
Cancer Treatment Reviews.2015; 41(2): 151. CrossRef
Tumour Budding and Survival in Stage II Colorectal Cancer: a Systematic Review and Pooled Analysis
F. Petrelli, E. Pezzica, M. Cabiddu, A. Coinu, K. Borgonovo, M. Ghilardi, V. Lonati, D. Corti, S. Barni
Journal of Gastrointestinal Cancer.2015; 46(3): 212. CrossRef
Tumor Budding in Colorectal Carcinoma
Rondell P. Graham, Robert A. Vierkant, Lori S. Tillmans, Alice H. Wang, Peter W. Laird, Daniel J. Weisenberger, Charles F. Lynch, Amy J. French, Susan L. Slager, Yassaman Raissian, Joaquin J. Garcia, Sarah E. Kerr, Hee Eun Lee, Stephen N. Thibodeau, James
American Journal of Surgical Pathology.2015; 39(10): 1340. CrossRef
Tumor budding in the clinical management of colon and rectal cancer
Viktor H Koelzer, Inti Zlobec, Alessandro Lugli
Colorectal Cancer.2014; 3(4): 387. CrossRef
Tumour budding and the expression of cancer stem cell marker aldehyde dehydrogenase 1 in nasopharyngeal carcinoma
Wei‐Ren Luo, Fei Gao, Si‐Yi Li, Kai‐Tai Yao
Histopathology.2012; 61(6): 1072. CrossRef
Tumor budding in colorectal carcinoma: time to take notice
Bojana Mitrovic, David F Schaeffer, Robert H Riddell, Richard Kirsch
Modern Pathology.2012; 25(10): 1315. CrossRef
Prognostic significance of tumor budding in gastrointestinal tumors
Bruno Märkl, Hans M Arnholdt
Expert Review of Anticancer Therapy.2011; 11(10): 1521. CrossRef
The Prognostic Significance of Fascin Expression in Colorectal Carcinoma
Jeong Min Lee, Jong Hun Lee, Mee Sook Roh, Ki Jae Park
Intestinal Research.2010; 8(2): 117. CrossRef

9,778 View
50 Download
20 Crossref

Synergistic Effect of Ionizing Radiation and β-lapachone against RKO Human Colon Adenocarcinoma Cells: Eun Jung Kim, In-Mi Ji, Ki-Jung Ahn, Eun Kyung Choi, Heon-Jin Park, Byung Uk Lim, Chang W. Song, Heon Joo Park; Cancer Res Treat. 2005;37(3):183-190. Published online June 30, 2005; DOI: https://doi.org/10.4143/crt.2005.37.3.183

Abstract PDF PubReader ePub

Purpose

To reveal the interaction between β-Lapachone (β-lap) and ionizing radiation in causing cell death in RKO human colon adenocarcinoma cells, and to elucidate the potential usefulness of combined β-lap treatment and radiotherapy for cancer treatment.

Materials and Methods

The cytotoxicities of various treatments were determined in vitro using clonogenic and apoptotic cell death. The changes in cell cycle distribution were studied using flow cytometry and an in vitro kinase assay. The tumor growth was studied using RKO tumors grown s.c. in the hind leg BALB/c- nuslc nude mice.

Results

β-lap caused clonogenic cell death and rapid apoptosis in RKO cells in vitro, in a dose dependent manner. The repair of sublethal radiation damage was almost completely inhibited when cells were maintained in β-lap during the interval between the two-dose irradiation. Flow cytometry study demonstrated that β-lap induced apoptosis, independent of the cell cycle phase, and completely prohibited the induction of radiation-induced G2 arrest in irradiated cells. The prohibition of radiation-induced G2 arrest is unclear, but may be related to the profound suppression of the p53, p21 and cyclin B1-Cdc2 kinase activities observed in cells treated with β-lap. The combination of β-lap and radiation markedly enhanced the radiation-induced growth suppression of tumors.

Conclusion

β-lap is cytotoxic against RKO cells, both in vitro and in vivo, and also sensitized cells to ionizing radiation by inhibiting sublethal radiation damage repair. β-lap is potentially useful as a potent anti-cancer chemotherapy drug and potent radiosensitizer against caner cells.

Citations

Citations to this article as recorded by

Chlorogenic Acid Enhances Beta‐Lapachone‐Induced Cell Death by Suppressing Autophagy in NQO1‐Positive Cancer Cells
Sahib Zada, Md Entaz Bahar, Wanil Kim, Deok Ryong Kim
Cell Biology International.2025;[Epub] CrossRef
Artemisia annua L. Polyphenols Enhance the Anticancer Effect of β-Lapachone in Oxaliplatin-Resistant HCT116 Colorectal Cancer Cells
Eun Joo Jung, Hye Jung Kim, Sung Chul Shin, Gon Sup Kim, Jin-Myung Jung, Soon Chan Hong, Choong Won Kim, Won Sup Lee
International Journal of Molecular Sciences.2023; 24(24): 17505. CrossRef
Radiotherapy-induced metabolic hallmarks in the tumor microenvironment
Anjali Mittal, Minal Nenwani, Itisam Sarangi, Abhinav Achreja, Theodore S. Lawrence, Deepak Nagrath
Trends in Cancer.2022; 8(10): 855. CrossRef
Natural products as chemo-radiation therapy sensitizers in cancers
Sabah Nisar, Tariq Masoodi, Kirti S. Prabhu, Shilpa Kuttikrishnan, Lubna Zarif, Summaiya Khatoon, Shahid Ali, Shahab Uddin, Ammira Al-Shabeeb Akil, Mayank Singh, Muzafar A. Macha, Ajaz A. Bhat
Biomedicine & Pharmacotherapy.2022; 154: 113610. CrossRef
Beta-Lapachone Attenuates BMSC-Mediated Neuroblastoma Malignant Transformation by Inhibiting Gal-3/Gal-3BP/IL6 Axis
Yang Zhou, Hui Yan, Qiang Zhou, Ruiling Feng, Penggao Wang, Fang Yang, Yaodong Zhang, Ziqiao Yuan, Bo Zhai
Frontiers in Pharmacology.2021;[Epub] CrossRef
Napabucasin (BBI 608), a potent chemoradiosensitizer in rectal cancer
Ganji Purnachandra Nagaraju, Batoul Farran, Matthew Farren, Gayathri Chalikonda, Christina Wu, Gregory B. Lesinski, Bassel F. El‐Rayes
Cancer.2020; 126(14): 3360. CrossRef
Using a novel NQO1 bioactivatable drug, beta‐lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer
Muhammad Shaalan Beg, Xiumei Huang, Molly A. Silvers, David E. Gerber, Joyce Bolluyt, Venetia Sarode, Farjana Fattah, Ralph J. Deberardinis, Matthew E. Merritt, Xian‐Jin Xie, Richard Leff, Daniel Laheru, David A. Boothman
Journal of Surgical Oncology.2017; 116(1): 83. CrossRef
2-[(4-Chlorophenyl)selanyl]-3,4-dihydro-2H-benzo[h]chromene-5,6-dione: crystal structure and Hirshfeld analysis
Julio Zukerman-Schpector, Karinne E. Prado, Luccas L. Name, Rodrigo Cella, Mukesh M. Jotani, Edward R. T. Tiekink
Acta Crystallographica Section E Crystallographic Communications.2017; 73(6): 918. CrossRef
β-Lapachone induces programmed necrosis through the RIP1-PARP-AIF-dependent pathway in human hepatocellular carcinoma SK-Hep1 cells
E J Park, K-j Min, T-J Lee, Y H Yoo, Y-S Kim, T K Kwon
Cell Death & Disease.2014; 5(5): e1230. CrossRef
Enhancement of radiation effect using beta-lapachone and underlying mechanism
Ki Jung Ahn, Hyung Sik Lee, Se Kyung Bai, Chang Won Song
Radiation Oncology Journal.2013; 31(2): 57. CrossRef

8,870 View
55 Download
10 Crossref

Enhancement of Radiation Effects by Flavopiridol in Uterine Cervix Cancer Cells: Suzy Kim, Hong-Gyun Wu, Jin Hee Shin, Hye Jin Park, In Ah Kim, Il Han Kim; Cancer Res Treat. 2005;37(3):191-195. Published online June 30, 2005; DOI: https://doi.org/10.4143/crt.2005.37.3.191

Abstract PDF PubReader ePub

Purpose

To determine the effects of combinations of radiation and flavopiridol, an inhibitor of cyclin-dependent kinases and global transcription, in a human uterine cervix cancer cell line.

Materials and Methods

Human uterine cervix cancer cells (HeLa), cultured to the mid-log phase, were exposed to X-rays, flavopiridol, and combinations of X-rays and flavopiridol in various sequences. The end point in this study was the clonogenic survival, which was measured via clonogenic assays. In order to determine the intrinsic cytotoxicity of flavopiridol, 0, 5, 12.5, 25, 37.5, 50 and 100 nM of flavopiridol were added to cell culture media. In the combination treatment, four different schedules of flavopiridol and irradiation combinations were tested: treatment of flavopiridol for 24 hours followed by irradiation, simultaneous administration of flavopiridol and irradiation, and irradiation followed by flavopiridol (for 24 hours) at intervals of 6 and 24 hours. The fraction of cells surviving after the combination treatment with 2 Gy of radiation (SF2) was compared with that of the fraction of cells surviving after treatment with irradiation alone.

Results

The cytotoxicity of flavopiridol was found to be dose-dependent, with an IC50 of 80 nM. No cytotoxic enhancements were observed when flavopiridol and radiation were administered simultaneously. Flavopiridol, administered either 24 hours before or 6 hours after irradiation, exerted no sensitizing effects on the cells. Only one protocol resulted in a radiosensitizing effect: the administration of flavopiridol 24 hours after irradiation.

Conclusion

Flavopiridol enhanced the effects of radiation on a uterine cervix cancer cell line in vitro, and this enhancement was both sequence- and time-dependent.

Citations

Citations to this article as recorded by

Flavopiridol: a promising cyclin-dependent kinase inhibitor in cancer treatment
Uttam Singh Baghel, Priyanka Kriplani, Neelam M. Patel, Manpreet Kaur, Kapil Sharma, Monika Meghani, Abhay Sharma, Deeksha Singh, Bhawani Singh, William N. Setzer, Javad Sharifi-Rad, Daniela Calina
Naunyn-Schmiedeberg's Archives of Pharmacology.2025; 398(4): 3489. CrossRef
BAIRDA: a novel in vitro setup to quantify radiobiological parameters for cervical cancer brachytherapy dose estimations
Braden Chow, Brad Warkentin, Kareena Nanda, Sunita Ghosh, Fleur Huang, Armin M Gamper, Geetha Menon
Physics in Medicine & Biology.2022; 67(4): 045012. CrossRef
Nutraceutical Compounds as Sensitizers for Cancer Treatment in Radiation Therapy
Marco Calvaruso, Gaia Pucci, Rosa Musso, Valentina Bravatà, Francesco P. Cammarata, Giorgio Russo, Giusi I. Forte, Luigi Minafra
International Journal of Molecular Sciences.2019; 20(21): 5267. CrossRef
Repositioning disulfiram as a radiosensitizer against atypical teratoid/rhabdoid tumor
Young Eun Lee, Seung Ah Choi, Pil Ae Kwack, Hak Jae Kim, Il Han Kim, Kyu-Chang Wang, Ji Hoon Phi, Ji Yeoun Lee, Sangjoon Chong, Sung-Hye Park, Kyung Duk Park, Do Won Hwang, Kyeung Min Joo, Seung-Ki Kim
Neuro-Oncology.2017; 19(8): 1079. CrossRef
Interaction of ω-3 polyunsaturated fatty acids with radiation therapy in two different colorectal cancer cell lines
Fang Cai, Olivier Sorg, Virginie Granci, Elena Lecumberri, Raymond Miralbell, Yves M. Dupertuis, Claude Pichard
Clinical Nutrition.2014; 33(1): 164. CrossRef
Antitumor Effects of Flavopiridol on Human Uterine Leiomyoma In Vitro and in a Xenograft Model
Hyun-Gyo Lee, Jong-Woo Baek, So-Jin Shin, Sang-Hoon Kwon, Soon-Do Cha, Won-Jin Park, Rosa Chung, Eun-Som Choi, Gun-Ho Lee, Chi-Heum Cho
Reproductive Sciences.2014; 21(9): 1153. CrossRef
In VitroRadiosensitization of Flavopiridol Did Not Translated intoIn VivoRadiosensitization
Suzy Kim
The Journal of the Korean Society for Therapeutic Radiology and Oncology.2011; 29(2): 83. CrossRef
Gold Nanoparticles as Radiation Sensitizers in Cancer Therapy
Devika B. Chithrani, Salomeh Jelveh, Farid Jalali, Monique van Prooijen, Christine Allen, Robert G. Bristow, Richard P. Hill, David A. Jaffray
Radiation Research.2010; 173(6): 719. CrossRef

9,448 View
51 Download
8 Crossref

Correlative Effect between in vivo Hollow Fiber Assay and Xenografts Assay in Drug Screening: Keyong Ho Lee, Ki Hyeong Rhee; Cancer Res Treat. 2005;37(3):196-200. Published online June 30, 2005; DOI: https://doi.org/10.4143/crt.2005.37.3.196

Abstract PDF PubReader ePub

Purpose

This study was carried out to assess the usage of an in vivo hollow fiber assay to screen drugs with highly predictive accuracy.

Materials and Methods

The assay systems used were the hollow fiber and xenografts assays. The hollow fiber assay was carried out with the following steps; preparation of fibers, preparation of cells, loading and implanting fibers, treatment with drugs, removal of fibers and assaying for the cell viability by the MTT assay. For the xenografts assay, cell suspensions were subcutaneously transplanted into the mice. Therapy was started when the tumor volume reached 100~200 mm³. The tumor volumes were calculated using the formula V=[length+(width)²]/2, and used for evaluating the efficacy of the drugs. The drug treatment doses used were adriamycin 2.1 mg/kg, mitomycin-C 0.25 mg/kg, 5-fluorouracil 24.5 mg/kg and paclitaxel 2.5 mg/kg, and administrated intravenously five times daily.

Results

The correlation between the xenografts and hollow fiber assays was evaluated in 20 tumor cell lines and 4 anti-cancer agents. In the 20 tumor cell lines, the overall predictive accuracy of the hollow fiber assay for sensitivity was 83%, with a predictive accuracy for resistance of 92%.

Conclusion

The hollow fiber assay was assessed as effective in drug efficacy evaluation, and found to be compatible with that of the xenografts assay.

Citations

Citations to this article as recorded by

Hu-Qi-Zheng-Xiao Decoction Inhibits the Metastasis of Hepatocellular Carcinoma Cells by Suppressing the HIF-1α Signaling Pathway to Inhibit EMT, LCSC, and Angiogenic Process
Xuejing Wang, Ling Yin, Mengyin Chai, Buxin Kou, Xiaoni Liu, Xiaojun Wang
Integrative Cancer Therapies.2024;[Epub] CrossRef
Models used to screen for the treatment of multidrug resistant cancer facilitated by transporter-based efflux
Clarissa Willers, Hanna Svitina, Michael J. Rossouw, Roan A. Swanepoel, Josias H. Hamman, Chrisna Gouws
Journal of Cancer Research and Clinical Oncology.2019; 145(8): 1949. CrossRef
Characterization of drug responses of mini patient‐derived xenografts in mice for predicting cancer patient clinical therapeutic response
Feifei Zhang, Wenjie Wang, Yuan Long, Hui Liu, Jijun Cheng, Lin Guo, Rongyu Li, Chao Meng, Shan Yu, Qingchuan Zhao, Shun Lu, Lili Wang, Haitao Wang, Danyi Wen
Cancer Communications.2018; 38(1): 1. CrossRef
Anti-tumor Activity of Saussurea laniceps against Pancreas Adenocarcinoma
Keyong Ho Lee, Byeong-Soo Kim, Ki-Hyeong Rhee
Natural Product Sciences.2017; 23(4): 281. CrossRef
Preclinical Efficacy Testing for Stomach and Liver Cancers
Jun Won Park, Nam Suk Baek, Seok Cheol Lee, Su Jin Oh, Seok Hoon Jang, In Hoo Kim, Dae Yong Kim, Hark Kyun Kim
Cancer Research and Treatment.2014; 46(2): 186. CrossRef
Novel approaches to glioma drug design and drug screening
Shivaputra A Patil, Amira Hosni-Ahmed, Terreia S Jones, Renukadevi Patil, Lawrence M Pfeffer, Duane D Miller
Expert Opinion on Drug Discovery.2013; 8(9): 1135. CrossRef

9,150 View
94 Download
6 Crossref

First
Prev
Page of 1
Next
Last

Previous issues